Unknown

Dataset Information

0

Discovery of Axelopran (TD-1211): A Peripherally Restricted ?-Opioid Receptor Antagonist.

ABSTRACT: The effects of opioids in the central nervous system (CNS) provide significant benefit in the treatment of pain but can also lead to physical dependence and addiction, which has contributed to a growing opioid epidemic in the United States. Gastrointestinal dysfunction is an additional serious consequence of opioid use, and this can be treated with a localized drug distribution of a non-CNS penetrant, peripherally restricted opioid receptor antagonist. Herein, we describe the application of Theravance's multivalent approach to drug discovery coupled with a physicochemical property design strategy by which the N-substituted-endo-3-(8-aza-bicyclo[3.2.1]oct-3-yl)-phenyl carboxamide series of ?-opioid receptor antagonists was optimized to afford the orally absorbed, non-CNS penetrant, Phase 3 ready clinical compound axelopran (TD-1211) 19i as a potential treatment for opioid-induced constipation.

SUBMITTER: Long DD 

PROVIDER: S-EPMC6912869 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

The effects of opioids in the central nervous system (CNS) provide significant benefit in the treatment of pain but can also lead to physical dependence and addiction, which has contributed to a growing opioid epidemic in the United States. Gastrointestinal dysfunction is an additional serious consequence of opioid use, and this can be treated with a localized drug distribution of a non-CNS penetrant, peripherally restricted opioid receptor antagonist. Herein, we describe the application of Ther  ...[more]

Similar Datasets

Unknown Diuretic Activity of a Novel Peripherally-Restricted Orally-Active Kappa Opioid Receptor Agonist.
| S-EPMC6780874 | biostudies-literature
Unknown Blocking Alcoholic Steatosis in Mice with a Peripherally Restricted Purine Antagonist of the Type 1 Cannabinoid Receptor.
| S-EPMC7607848 | biostudies-literature
Unknown Pharmacologic effects of naldemedine, a peripherally acting ?-opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation.
| S-EPMC6850587 | biostudies-literature
Unknown Peripherally Restricted, Highly Potent, Selective, Aqueous-Soluble EP2 Antagonist with Anti-Inflammatory Properties.
| S-EPMC6633905 | biostudies-literature
Unknown Novel Peripherally Restricted Cannabinoid 1 Receptor Selective Antagonist TXX-522 with Prominent Weight-Loss Efficacy in Diet Induced Obese Mice.
| S-EPMC5633609 | biostudies-literature
Unknown Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch.
| S-EPMC8635029 | biostudies-literature
Unknown A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents.
| S-EPMC2990160 | biostudies-literature
Unknown Peripherally restricted cannabinoid type 1 receptor (CB1R) antagonist, AM6545, potentiates stress-induced hypothalamic-pituitary-adrenal axis activation via a non-CB1R mechanism.
| S-EPMC8528513 | biostudies-literature
Unknown Naloxegol: First oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation.
| S-EPMC4544149 | biostudies-literature
Unknown Peripherally restricted transthyretin-based delivery system for probes and therapeutics avoiding opioid-related side effects.
| S-EPMC9226319 | biostudies-literature